Thursday, 18 April 2013

Athersys to expand Phase II clinical trial of MultiStem on ischemic stroke patients

Yesterday, Athersys announced that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), to expand its ongoing Phase II trial on MultiStem to ischemic stroke patients.

Purpose of this double blind, placebo-controlled trial is to evaluate the safety and efficacy of MultiStem's stem cells in patients who had a "moderate to moderately severe stroke", with a NIHSS score of 8 to 20. According to the company's website, MultiStem is a patented biologic product containing stem cells manufactured from human stem cells, originally extracted from adult bone marrow or other non embryonic tissue sources. MultiStem has shown promise in treating cardiovascular, neurological, inflammatory and immune-related diseases.

In this trial, a total of 136 patients are expected to enrol, who will receive, 24-36 hours after the stroke, a single intravenous dose of MultiStem stem cells (or placebo). At the moment, the trial is conducted in many U.S centres.
"The MHRA authorisation will enable us to bring several leading United Kingdom stroke centres into the study, which will help us to speed the completion of the stroke clinical trial. The authorisation is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom." said Dr. Gil Van Bokkelen, Chairman and CEO of Athersys.


Video about Multistem


Athersys is a a biopharmaceutical company, established in October, 1995. The company is focused in the development of new therapies "designed to extend and enhance the quality of human life". Athersys has forged strategic partnerships with Pfizer to develop MultiStem for inflammatory bowel disease and with RTI Biologics, to develop cell therapy for use with a bone allograft product in the orthopaedic market.



Related Posts
Allogeneic stem cells aid in ischemic stroke recovery: An animal study shows stem cells from bone marrow and fat tissue may hold the key for treating damages induced after an ischemic stroke. 


You can read the official press release here

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !